LNDC Landec Corp.

Landec Appoints New Chief Financial Officer

Landec Appoints New Chief Financial Officer

SANTA MARIA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC), a diversified health and wellness company with two operating businesses, Curation Foods, Inc. and Lifecore Biomedical, Inc., today announced the appointment of John D. Morberg as Chief Financial Officer, effective January 18, 2021. Mr. Morberg succeeds Brian McLaughlin, Landec’s current Chief Financial Officer, who has retired. Mr. Morberg will report to Landec’s President and Chief Executive Officer, Dr. Albert Bolles, and will oversee the Company’s finance, legal and investor relations functions.

Dr. Bolles stated, “We are excited to welcome John as our new Chief Financial Officer. He brings tremendous strategic and financial capabilities that we believe will be key as we continue to deliver improvements and advance our growth agenda, and to seek to position the company for resilience and profitability. He is well-aligned with our culture and will be a strong addition to Landec’s executive management team.” Dr. Bolles added, “I would also like to thank Brian McLaughlin for all of his contributions to the company and wish him well in his retirement.”

Mr. Morberg brings over 25 years of corporate finance and executive leadership experience with both public and private companies, including as a CEO, CFO, general counsel and board member. Most recently, he was CFO and General Counsel for BL Restaurant Holdings, LLC, a national restaurant chain. Previously, over a ten-year tenure at Garden Fresh Restaurant Corp, he held various roles, including as the CEO, CFO and board member. He also served as CFO of DEI Holdings, Inc., through its initial public offering and through the early stages of being a public company, and worked for eight-years as Vice President and Controller of PETCO. Mr. Morberg began his career at KPMG.

Mr. Morberg has a Juris Doctor from the University of the Pacific, McGeorge School of Law and a BBA, Accounting from the University of San Diego. He is a member of the State Bar of California and holds a CPA license (inactive).

“I am excited to assume the CFO role at Landec to help the company continue executing its strategic plan, accelerate growth and deliver value to shareholders,” said Mr. Morberg. “I look forward to partnering with the leadership team and the entire company on this journey.”

About Landec Corporation

Landec Corporation (NASDAQ: LNDC) is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc. Landec designs, develops, manufactures and sells products for the food and biopharmaceutical industry. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Landec’s website at .

Contact Information:
 
Investor Relations:
Jeff Sonnek
(646) 277-1263

 



EN
19/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Biomedical to Report Financial Results for the Three Months E...

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...

 PRESS RELEASE

Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...

 PRESS RELEASE

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-...

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical custom...

 PRESS RELEASE

Lifecore Biomedical to Participate at Upcoming Industry Conferences an...

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows: 15th Annual Partnership Opportunities in Drug Development (PODD)Conference Dates/Location: October 27-28, 2025, in Boston, MADetails: Ryan Swanson, Ph.D., Lifecore’s director of pro...

 PRESS RELEASE

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired em...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch